An Open-label, Non-controlled, Multicentre, Pilot Clinical Trial of Inhaled Molgramostim in Subjects With Antibiotic-resistant Non-tuberculosis Mycobacterial (NTM) Infection

Trial Profile

An Open-label, Non-controlled, Multicentre, Pilot Clinical Trial of Inhaled Molgramostim in Subjects With Antibiotic-resistant Non-tuberculosis Mycobacterial (NTM) Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Bacterial infections; Mycobacterial infections
  • Focus Therapeutic Use
  • Acronyms OPTIMA
  • Sponsors Savara Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 29 Jan 2018 Status changed from planning to not yet recruiting.
    • 16 Nov 2017 According to a Savara media release, this Phase IIa study is expected to be initiated in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top